Dr Andrew Woo

I am a Senior Lecturer in Clinical Biochemistry in the School of Medical, Molecular and Forensic Sciences. I am actively involved in both teaching and research, leading innovative projects in stem cell biology and cancer at the Harry Perkins Institute of Medical Research. There, I also supervise Higher Degree by Research (HDR) students from several Western Australian universities.

Current Teaching

Unit Co-ordinator, lecturer and Tutor for:

• BMS323 Clinical Biochemistry I
• BMS423 Clinical Biochemistry II

Background

Dr Woo is a biomedical scientist specializing in transcriptional gene regulation, with research impacting blood disorders, cancer, and stem cell biology. He completed his PhD at UWA and postdoctoral training at Harvard Medical School. Dr Woo has published in leading journals such as Cell, Cancer Cell, Journal of Clinical Investigation and Blood. He holds academic appointments at Edith Cowan University and the University of Western Australia.

Employment history:

• 2020-Present: Lecturer and Unit Co-ordinator, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA
• 2012-Present: Research Fellow, Harry Perkins Institute of Medical Research, University of Western Australia, Perth, WA
• 2004-2012: Postdoctoral Research Fellow, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Grants and Funding Awards:

• 2024 - Chief Investigator A (CIA) Andrew Woo., et al., Targeting an alternate nuclear receptor to treat aggressive breast cancers. Cancer Council WA. A$137,735.
• 2024 - CIE Andrew Woo., et al., Epigenome engineering for the therapeutic reprogramming of the mesenchymal to epithelial states in breast cancer. NHMRC. A$2,887,937.
• 2024 - CIE Andrew Woo., et al., Therapeutic exploitation of Rab12, a novel tumour and metastasis suppressor in breast cancer. Cancer Council WA. A$120,000.
• 2023 - CIA Andrew Woo., et al., Targeting breast cancer stem cells for therapy. HPIMR. A$100,000.
• 2022 - CIC Andrew Woo., et al., Epigenetic reprogramming of the mesenchymal transcription factor network in triple negative breast cancer. Cancer Australia. A$119,349.
• 2021 - CIA Andrew Woo. et al., Boosting platelet supply for transfusion: Cellular reprogramming approach. Department of Health, WA. A$74,000.
• 2017 - CIE Andrew Woo., et al., Characterisation of a new subtype of aggressive breast cancer. NHMRC. A$763,152.
• 2016 - CIA Andrew Woo., et al., Reprogramming metastatic tumours: Investigating the role of the ZBP family of transcription factors. Department of Health, WA. A$75,000.
• 2016 - CIE Andrew Woo., et al., Discovery and Characterisation of a Cancer Driver in a New Subtype of Aggressive Breast Cancer., Cancer Council WA. A$100,000.
• 2016 - CIA Andrew Woo., et al., Reprogramming metastatic tumours: Investigating the role of the ZBP family of transcription factors. Cancer Council WA. 2016-2017. A$100,000.
• 2015 - Associate Investigator Andrew Woo., et al., Nuclear receptors and triple negative breast cancer., NHMRC. A$681,979.
• 2015 - CIA Andrew Woo., et al., Dissecting ZBP TF-Associated Oncogenic Pathways in Epithelial Cancers. Medical Research Foundation.A$17,500.
• 2014 - CIA Andrew Woo., et al., Investigating the role of Zfp148 in immune function and epithelial cancers. Medical Research Foundation. A$17,500.
• 2013 - CIA Andrew Woo., et al., Functional examination of the ZBP family of transcription factors in cancer metastasis. Medical Research Foundation. A$20,000.